年薪千万元、"最牛打工人"、职业经理人"天花板"......美的集团董事长兼总裁方洪波，在商界拥有耀眼的光环。 以美的视角看，方洪波值得称赞之处在于，既非美的创始元老，也非第一大股东，这突破了民企股权与管理权深度绑定的传统结构。 在这种情况下，方洪波接班12年，推动美的营收增长298%、净利润增长531%、自有资金增长4512%、资产总额增长589%（数据源自美的集团官网，与 2013年年度报告对比存在偏差），市值峰值一度突破7000亿元。方洪波带领美的拳打格力、脚踢海尔，将美的推向了中国"家电一哥"的位置。 更可贵的是，方洪波多次表示"我一定要退下来""我只是美的发展历史中的一个过客"……他对外展示的个人形象非常鲜明——不恋权、不恋名，随时准备 隐入尘烟。 当然，美的集团也没有亏待这位功臣。 天眼查显示，方洪波持有美的集团1.17亿股，占美的集团总股本1.52%。按1月30日开盘价77.60元计算，方洪波身价达到91.84亿元。《2025新财富500创富 榜》显示，方洪波以88.1亿元的持股估值，位列第391位。 在薪酬上，美的也给予了方洪波"天价"回报。2024年美的年度报告显示，方洪波从公司获得的税前报 ...

Group 1 - The core point of the article is that Wandong Medical (600055.SH) has repurchased a total of 1,802,700 shares through centralized bidding, representing 0.2564% of the company's total share capital [1] - The highest purchase price for the repurchased shares was 17.99 yuan per share, while the lowest was 15.71 yuan per share [1] - The total amount paid for the repurchased shares, excluding transaction fees, was 29,992,822.08 yuan [1]

Core Viewpoint - WanDong Medical (600055.SH) has announced a share buyback program, indicating a strategic move to enhance shareholder value and confidence in the company's future prospects [1] Group 1: Share Buyback Details - As of the end of January 2026, the company has repurchased a total of 1,802,700 shares through centralized bidding, which represents 0.2564% of the company's total share capital [1] - The highest purchase price for the repurchased shares was 17.99 yuan per share, while the lowest was 15.71 yuan per share [1] - The total amount paid for the repurchased shares, excluding transaction fees, was 29,992,822.08 yuan [1]

证券代码：600055 证券简称：万东医疗 公告编号：临 2026-011 2025 年 8 月 22 日，北京万东医疗科技股份有限公司（以下简称"公司"） 召开第十届董事会第十次会议，审议通过《关于以集中竞价交易方式回购公 司股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购公司股 份，用于员工持股计划或股权激励，回购股份金额为人民币 3,000 万元（含） -6,000 万元（含），回购股份价格不超过人民币 25 元/股，实施期限为自公司 第十届董事会第十次会议审议通过本次回购方案之日起 12 个月内。具体内容 详见公司于 2025 年 8 月 23 日在上海证券交易所网站披露的《万东医疗关于 以集中竞价交易方式回购股份方案的公告》（公告编号：临 2025-038）。 二、 回购股份的进展情况 北京万东医疗科技股份有限公司 关于股份回购进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/8/23 | | | | | | --- | --- | --- ...

证券代码：600055 证券简称：万东医疗 公告编号：2026-010 北京万东医疗科技股份有限公司 关于公司及子公司使用闲置募集资金 及自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 产品种类：银行理财 本次现金管理总额：募集资金 1 亿元、自有资金 2.1 亿元 履行的审议程序：2025年 3月 20日召开的第十届董事会第六次会议、 第十届监事会第六次会议及 2025 年 4 月 16 日召开的 2024 年年度股东大会 审议批准《关于使用部分暂时闲置募集资金及自有资金进行现金管理的议 案》。 一、情况概述 （一）现金管理目的 北京万东医疗科技股份有限公司（以下简称"公司"）及子公司为提 高募集资金和自有资金效率，合理利用部分闲置募集资金及自有资金，在 确保不影响募集资金项目建设和使用、募集资金和自有资金安全的情况下， 增加公司的收益，为公司及股东获取更多回报。 （二）现金管理金额 本次现金管理总金额为：公司使用募集资金 1 亿元,自有资金 1 亿元； 子公司使用自有资金 1.1 亿元 ...

Core Viewpoint - The company plans to repurchase shares through centralized bidding, with a total amount between 30 million to 60 million yuan, at a price not exceeding 25 yuan per share, with the implementation period until August 21, 2026 [1] Summary by Relevant Sections - **Share Repurchase Plan**: The company has announced a share repurchase plan set to begin on August 22, 2025, with a budget of 30 million to 60 million yuan, and a maximum purchase price of 25 yuan per share [1] - **Implementation Timeline**: The repurchase will be executed until August 21, 2026 [1] - **Current Repurchase Status**: As of the end of January 2026, the company has repurchased a total of 1.8027 million shares, representing 0.2564% of the total share capital, with a total expenditure of approximately 29.9928 million yuan, at prices ranging from 15.71 yuan to 17.99 yuan per share [1] - **Unexecuted Repurchase**: No repurchase was executed in January 2026 [1]

医药企业近日陆续披露年报预告，据东方财富Choice数据统计，截至目前，A股医药生物板块有137家 企业预告2025年亏损，其中首亏、增亏的企业数量占比一半以上；而预计去年归属于母公司的净利润亏 损最高的，达到137亿元。 药企亏损的背后，受制于多方面因素，其中产品价格下跌成为高频词。 亏损最高的超百亿 具体看这137家预告亏损的医药生物企业，涵盖了原料药、化学制剂、中药、疫苗、医药流通、体外诊 断、医疗耗材、医疗研发外包、医疗设备等细分领域，从预告归属于母公司的净利润下限指标看，亏损 最大的是智飞生物（300122.SZ），去年业绩首亏，公司预计归属于母公司的净利润亏损最高可达到 137.26亿元；紧接着是珍宝岛（603567.SH），预计去年归属于母公司的净利润亏损最高可达到11.73亿 元；之后是百利天恒（688506.SH），预计去年归属于母公司的净利润亏损最高可达到11亿元。 另外，蓝帆医疗（002382.SZ）、神州细胞（688520.SH）、润达医疗（603108.SH）、广济药业 （000952.SZ）这四家企业预计去年归属于母公司的净利润亏损最高可超过5亿元。 A股医药生物板块企业的亏损，受 ...

Core Viewpoint - WanDong Medical (600055) expects a net profit loss of approximately 199 million to 257 million yuan for the fiscal year 2025, with a net profit loss excluding non-recurring gains and losses estimated at 213 million to 271 million yuan [1] Group 1: Financial Performance - The company has adjusted its marketing strategy to adapt to market changes, successfully winning imaging equipment projects with more competitive pricing, which has impacted gross margins and compressed net profit margins [1] - The anticipated losses for 2025 reflect the challenges faced in maintaining profitability amid strategic shifts and market conditions [1] Group 2: Strategic Initiatives - The company is increasing its R&D investment and actively expanding into overseas markets while strengthening marketing efforts in high-grade domestic hospitals, contributing to its strategic transformation towards high-end and international markets [1] - To address structural challenges in the industry, the company is hiring specialized R&D personnel and enhancing its comprehensive layout in high-end medical imaging equipment, particularly in CT, MR, and DSA categories [1] Group 3: Technological Development - The company focuses on the R&D of core components and high-performance equipment, establishing a technology reserve framework of "research generation, reserve generation, and development generation" [1] - Efforts to deepen overseas market penetration include improving the overseas marketing organizational structure and functions, implementing overseas station expansions, and building regional service centers to enhance medical accessibility [1]

Group 1 - The core viewpoint of the news is that Wandong Medical is expected to report significant losses in 2025, transitioning from profit to loss due to various operational challenges [1][3]. Group 2 - As of January 30, 2026, Wandong Medical's stock closed at 15.94 yuan, with a trading volume of 59,200 shares and a total transaction amount of 94.49 million yuan [1]. - On January 30, the net inflow of main funds was 272,500 yuan, accounting for 0.29% of the total transaction amount, while retail investors saw a net outflow of 287,290 yuan, representing 3.04% of the total [1][3]. Group 3 - Wandong Medical forecasts a net profit loss of between 199.73 million yuan and 257.83 million yuan for the year 2025, with a non-recurring net profit loss expected to be between 213.23 million yuan and 271.33 million yuan [1][3]. - The company attributes the expected losses to participation in centralized procurement of medical devices, adjustments in pricing strategies affecting gross margins, and increased investments in research and development as well as expansion into overseas and high-end markets [1][3].

Core Viewpoint - WanDong Medical (600055) is facing a significant financial downturn, with projected net losses for 2025, primarily due to increased competition and strategic investments in R&D and international markets [1][3]. Financial Performance - WanDong Medical anticipates a net profit loss of between 199 million to 257 million yuan for the year 2025, marking a shift from profit to loss compared to the previous year [1][3]. - The expected loss in net profit is attributed to participation in medical device procurement, which has led to a decrease in gross margin, alongside increased investments in research and development and overseas market expansion [1]. Company Announcements - On January 26, 2026, WanDong Medical held its 13th meeting of the 10th Board of Directors, where Wang Jianguo was elected as the new chairman, succeeding Ma Chibing, who resigned for personal reasons [1][2]. - The first extraordinary general meeting of shareholders in 2026 was also held on January 26, where Wang Jianguo was elected as a non-independent director with 98.3021% of the votes in favor [2]. - The Board's strategic committee has been adjusted to include Wang Jianguo, Song Jinsong, Zhong Zheng, and Liu Xiao, with Wang Jianguo serving as the convener [2].